News
Novel stroke treatment receives new US patent

A new twist on a drug used to treat alcohol use disorder could double up as a treatment for stroke.
Carb – short for Carbamathione – is a new formulation designed to treat ischemic stroke, protect brain tissue against injury and minimise the size of localised brain damage.
About 87% of all strokes are caused by a sudden disruption of blood supply to the brain. Whilst significant strides have been made in recent years in stroke research and care, effective treatments are still few and far between.
Now Jang-Yen (John) Wu, a professor of biomedical science in Florida Atlantic University’s Schmidt College of Medicine and the inventor of the Carb therapy, has received a new US patent for his work related to Carbamathione, that will open the door to the novel drug being commercialised.
According to the World Health Organisation, 15 million people a year globally suffer a stroke. Of these, five million die and another five million are left permanently disabled. The chance of suffering a stroke doubles every 10 years after the age of 55 with the most common age being 71.4 in men and 76.9 years in women.
The potential promise of Dr Wu’s discovery has enticed CHS Pharma Inc, a South Florida biotechnology company, to make the stroke treatment a reality. The firm has acquired this patent and four others related to neurological disorders and traumatic brain injury.
It is CHS’s intention to move forward with the Carb discovery through commercialisation.
Dr Wu said: “One of the novel aspects of using Carbamathione, or Carb therapy, to treat stroke is its safety. Carb is an active metabolite of disulfiram or DSF, which has been used to treat alcohol use disorder for more than six decades and has been found to be safe with minimal adverse effects.

Jang-Yen (John) Wu, inventor of ‘Carb’ therapy
“Once we are able to demonstrate the efficacy of Carb therapy in treating stroke, we will be able to use it on patients.”
Strides have been made in the field of brain injury brought on by inadequate blood supply (ischemia) and lack of oxygen (hypoxia), a major pathophysiology of stroke.
However, despite extensive research to develop medicines for stroke based on the known mechanisms, these efforts have largely failed to fulfil expectations.
Dr Wu said: “Attempts to develop medicines to treat stroke have been disappointing, partially because the underpinning mechanism of stroke-induced neuronal injury is multi-factorial and therefore needs a therapeutic intervention that addresses the multi-factorial nature of the disease.”
It is generally believed excitotoxicity caused by excessive release of excitatory neurotransmitter glutamate plays an important role in ischemia/reperfusion induced neuronal death.
Carb works by protecting ischemia-induced brain injury through its action as a glutamate receptor partial antagonist. This unique property could provide neuronal protection through its ability to block excessive glutamate-induced neuronal excitation while allowing the basal glutamate neurotransmission to continue.
Dr Wu said a pharmaceutically formulated version of Carb could be administered as an injection to treat patients diagnosed with an ischemic stroke.
“Unlike tissue plasminogen activator (TPA), which has a window of opportunity of only four hours, Carb could be administered within 24 hours of the onset of symptoms of ischemic stroke,” he explained.
Carb therapy also holds the promise to treat other diseases in the future as glutamate-induced excitotocixity is thought to be involved in many neurological diseases, including Alzheimer’s, epilepsy and others.
News
Longevity startup Biopeak secures US$2.7m
News
Study reveals link between cheese and dementia

A 25-year Swedish study links higher cheese intake to lower Alzheimer’s risk in people without known genetic risk, with cream also tied to lower dementia risk.
However, researchers emphasise that the results should be interpreted with caution.
The study tracked 27,670 people over 25 years.
During that time, 3,208 participants were diagnosed with dementia.
Among individuals without a known genetic risk for Alzheimer’s disease, those who consumed more than 50 grams of full-fat cheese per day showed a 13 to 17 per cent lower risk of developing Alzheimer’s.
This association did not appear in participants who carried genetic risk factors for the disease.
People who consumed more than 20 grams of full-fat cream per day also showed a lower risk of dementia overall, ranging from 16 to 24 per cent.
No meaningful links were found for low-fat or high-fat milk, fermented or non-fermented milk, or low-fat cream.
The results stand out because public health guidance has long encouraged people to choose low-fat dairy to protect heart health.
This connection matters because cardiovascular disease (conditions affecting the heart and blood vessels) and dementia share many underlying risk factors, including high blood pressure, diabetes and obesity.
When evidence from previous studies is combined, analyses suggest that cheese consumption may also be linked to a lower risk of heart disease, and that full-fat dairy does not necessarily increase cardiovascular risk.
Several other studies have explored whether similar patterns apply to brain health, but the results are mixed.
Evidence overall suggests that studies conducted in Asian populations are more likely to report benefits of dairy consumption for cognitive health (the ability to think, remember and reason), while many European studies do not.
One possible explanation is that average dairy intake tends to be much lower in Asian countries, meaning modest consumption may have different effects than higher intakes.
For example, one Japanese study reported a reduced dementia risk among people who ate cheese, but overall consumption levels were very low and the research was sponsored by a cheese producer.
In contrast, another Japanese study funded by government grants found no protective effect of cheese.
Some long-term European studies have also reported benefits.
In a Finnish study of 2,497 middle-aged men followed for 22 years, cheese was the only food associated with a lower dementia risk, reduced by 28 per cent.
Other dietary factors also appear to matter.
Higher consumption of milk and processed red meat was associated with worse performance on cognitive tests, while fish intake was linked to better results.
A large study in the UK that followed nearly 250,000 people found lower dementia risk among those who ate fish two to four times a week, fruit daily and cheese once a week.
However, these studies have important limitations.
What people eat is usually self-reported, and changes in memory can affect both eating habits and how accurately people remember what they have eaten. To deal with this, the Swedish researchers took two extra steps.
First, they excluded anyone who already had dementia when the study began.
Then they repeated the same calculations after removing people who went on to develop dementia within the first ten years of the study.
This did not mean starting the study again or recruiting new participants. It simply meant re-checking the results using a smaller group of people who remained dementia-free for longer.
The reason for doing this is that the early stages of dementia can subtly change behaviour long before diagnosis.
People may eat differently, lose appetite or struggle to recall their usual diet. By focusing on participants who stayed cognitively healthy for many years, the researchers reduced the chance that these early changes were influencing the results.
Another important question is whether substitution played a role.
Some of the apparent benefits may reflect replacing red or processed meat with cheese or cream, rather than an effect of dairy itself.
Supporting this idea, the Swedish study found no association between full-fat dairy and dementia risk among participants whose diets remained stable over five years.
Most importantly, foods should not be considered in isolation.
Dietary patterns matter more than individual ingredients. Diets such as the Mediterranean diet, which is consistently associated with lower risks of both dementia and heart disease, include cheese alongside vegetables, fish, whole grains and fruit.
In the Swedish study, people who consumed more full-fat cheese and cream were also more educated, less likely to be overweight and had lower rates of conditions linked to dementia, including heart disease, stroke, high blood pressure and diabetes.
All of these factors independently reduce dementia risk.
This suggests that higher cheese intake tended to occur within healthier overall lifestyles, rather than alongside excess calorie consumption or poor metabolic health.
Overall, the evidence does not support the idea that full-fat dairy causes dementia, nor that fermented milk products reliably protect against it.
Full-fat cheese contains several nutrients relevant to brain health, including fat-soluble vitamins A, D and K2, as well as vitamin B12, folate, iodine, zinc and selenium.
These nutrients play roles in neurological function and may help support cognitive health.
That said, the data do not justify eating large amounts of cheese or cream as protective foods against dementia or heart disease.
The most consistent message remains that balanced diets, moderation and overall lifestyle matter far more than any single item on the cheese board.
News
New obesity and diabetes drug set for Boots clinical trial
News3 weeks agoInterview: GlycanAge launch first hospital-based tests
News4 weeks agoCaptioning glasses win AARP pitch at CES
News4 weeks agoFood preservatives linked to increased diabetes and cancer risk, study finds
News2 weeks agoShingles vaccine may slow biological ageing in older adults
News3 weeks agoOlder male athletes may face increased risk of serious heart problems during exercise
News4 weeks agoCorsera Health raises US$80m to prevent heart disease
News3 weeks agoThousands of men in England to be offered life-extending prostate cancer drug
News4 weeks agoBillionaire Platt backs Engitix again with US$25m






















